Sat, Dec 20, 2014, 8:39 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

NovaBay Pharmaceuticals, Inc. Message Board

  • stevefranklin941@ymail.com stevefranklin941 Sep 13, 2013 11:17 AM Flag

    NBY

    An important perspective to keep in mind is that NBY's area of drug development, anti-infectives, has historically been the area with the highest clinical success rate. This is because companies focused on topical anti-microbials, such as NBY, know before they begin the first human clinical trial that their compounds kill the pathogens they are targeting. In NBY's case, they have already confirmed auriclosene's anti-viral capabilities against the adenoviruses that cause conjunctivitis, the staphylococcus aureus and MRSA bacteria implicated in impetigo and also the gram negative Proteus mirabilis bacteria that cause urinary catheter blockage and encrustation. Therefore, success in clinical trials is a matter of safety, concentration, formulation and dosing regimen.

    Sentiment: Strong Buy

 
NBY
0.67+0.0400(+6.35%)Dec 19 4:04 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Under Armour, Inc.
NYSEFri, Dec 19, 2014 4:04 PM EST
3M Company
NYSEFri, Dec 19, 2014 4:04 PM EST
8x8 Inc.
NASDAQFri, Dec 19, 2014 4:00 PM EST